# DESCRIPTION

## GOVERNMENT FUNDING

- acknowledge government support

## BACKGROUND

- introduce PIK3CA mutations

## SUMMARY

- describe PIK3CA helical domain mutations
- outline therapeutic approach

## DETAILED DESCRIPTION

- define terms used in the specification
- explain transitional phrases and indefinite articles
- describe ranges and endpoints
- define cancer and various types of cancer
- define responsiveness and therapeutic responses
- define sample and normal cell
- explain contacting a cell and candidate compound
- describe severity of cancer and its various aspects
- define symptom, sign, and subject
- explain therapeutically effective amount and treatment
- describe combination therapy
- outline administration methods
- define synergistic effect
- describe pharmaceutical compositions
- list EZH inhibitors
- list PI3K inhibitors
- discuss pharmaceutical composition formulation
- outline dosage and administration
- describe pharmaceutical compositions
- formulate oral compositions
- formulate injectable compositions
- formulate compositions for administration by inhalation
- formulate compositions for transmucosal or transdermal administration
- describe controlled release formulations
- describe dosage regimen
- describe techniques for formulation and administration
- describe subject to be treated
- describe specific cancers
- define breast cancer
- describe PIK3CA helical domain mutant cancer
- classify breast cancer by stage and grade
- describe tumor characteristics
- describe treatment outcomes
- describe decrease in tumor size and volume
- describe decrease in number of tumors and metastatic lesions
- describe increase in average survival time
- describe decrease in mortality rate
- describe decrease in tumor growth rate and regrowth
- describe detection of mutant PIK3CA helical domain

### Example 1

- describe cancer cell behavior with p110α helical domain mutation

### Materials & Methods

- describe cell culture and transfection
- outline DNA construct and mutagenesis
- explain CRISPR/CAS9 genome editing
- detail RNA extraction and quantitative real-time PCR
- summarize various cell growth and protein analysis assays

### Results

- investigate p110α helical domain mutant protein binding
- identify p85β dissociation from p110α helical domain mutant protein
- determine N-terminal p85β sequences cause dissociation
- explore p85β oncogenic role in cancer cells with PIK3CA helical domain mutation
- elucidate p85β nuclear translocation in cancer cells with PIK3CA helical domain mutation
- determine nuclear translocation of p85β
- identify role of p85β in tumorigenesis
- investigate stabilization of EZH1/2 by p85β
- examine recruitment of USP7 by p85β
- test combination therapy with EZH inhibitor and p110α inhibitor
- analyze efficacy of combination therapy in different tumor types
- discuss implications for cancer treatment

### Example 2

- demonstrate combination therapy

